Detalhe da pesquisa
1.
Incidence and reasons for discontinuation of first-line therapy in patients with multiple myeloma: results from a historical cohort, Brazil 2009-2020.
Ann Hematol
; 2024 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38459153
2.
HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review.
AIDS Care
; 31(10): 1234-1240, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31043069
3.
Effectiveness of second-line antiretroviral therapy: the impact of drug switches.
AIDS Care
; 29(12): 1585-1588, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28490196
4.
Real-world effectiveness and safety of multiple myeloma treatments based on thalidomide and bortezomib: A retrospective cohort study from 2009 to 2020 in a Brazilian metropolis.
Cancer Epidemiol
; 85: 102377, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163919
5.
Evaluation of primary health care by users and non-users of drugs hospitalized for primary care-sensitive conditions.
Aten Primaria
; 49(4): 258-260, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27639413
6.
Use of fall risk-increasing drugs in older adults with multiple myeloma: A cross-sectional study.
J Geriatr Oncol
; 13(4): 493-498, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086797
7.
Validation of an Instrument for Measuring Adherence to Treatment With Immunomodulators in Patients With Multiple Myeloma.
Front Pharmacol
; 12: 651523, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34045961